[01] Waled Mohamed Alsalmi, Department of Medical Laboratory, Faculty of Medical Technology, Surman, Sabratha University, Surman, Libya. [02] Laila Hamed Farag Shaglouf, Department of Medical Laboratory, Faculty of Medical Technology, Misalliata, Almergib University, Misalliata, Libya. [03] Azab Elsayed Azab, Department of Physiology, Faculty of Medicine, Sabratha University, Sabratha, Libya.

Background: It well is known that thyroid hormones are involved in regulation of lipid and lipoprotein metabolism; therefore, thyroid dysfunctions induce a significant change in lipid levels. Thyroid hormones are an important modulator of intermediary metabolism. Objectives: This study was conducted to observe the correlation between hypothyroidism, hyperthyroidism and lipid profile in thyroid dysfunction patients. Methods: The study group consists of 118 subjects of both sex (53 males & 65 females) between the age 20-87. The samples of these patients were collected from Asian Institute of Medical Science at Faridabad region. The subjects were divided into four groups the first group consisting 51 subjects for hypothyroidism which also divided into two subgroups 14 patients suffering from overt hypothyroidism and 37 patients suffer from sub-clinical hypothyroidism, second group for normal conditions or control which consist 20 subjects, third group consisting 14 patients suffering from hyperthyroidism, and last group consist 33 patient suffer cardiac disease. About 3 ml blood samples were collected to detect FT3, FT4, TSH, cholesterol, triglyceride, HDL-C, LDL-C, and VLDL–C analyzed in the lab of Asian Institute of Medical Science in Faridabad region. Results: The present study demonstrated multiple biochemical abnormalities in the serum lipids in hypothyroidism and hyperthyroidism subjects, there is an increase in the most lipid profile in both hypothyroid and hyperthyroid patients, and finally, dyslipidemia which is one of the major risk factors of atherosclerosis and coronary disease. There is an increase in total cholesterol, VLDL-C, and levels and decreased in HDL-C in hypothyroidism patients. And there is also increase in total and LDL cholesterol, and decreased in HDL-C level in hyperthyroidism patients, within no changes in VLDL and levels, and there is no significant between hypothyroidism and hyperthyroidism groups). Conclusion: This study concluded that there is an increase in the most lipid profile in both hypothyroid and hyperthyroid patients and finally dyslipidemia which is one of the major risk factors for atherosclerosis and coronary disease. There is an increase in total cholesterol, VLDL-C, and levels and decreased in HDL-C in hypothyroidism patients. And there is also increase in total and LDL cholesterol, and decreased in HDL-C level in hyperthyroidism patients.

Correlation, Thyroid Dysfunction, Hypothyroidism, Hyperthyroidism, Lipid Profile, Dyslipidemia

[01] American Thyroid Association. Hypothyroidism. Page 3 [02] Prasad R, and Kumar V (2005). Thyroid hormones increase Na+-Pi co-transport activity in intestinal brush border membrane: role of membrane lipid composition and fluidity. Molecular and Cellular Biochemistry, 278 (1-2): 195-202. [03] Alfadda AA, Benabdelkamel H, Masood A, Jammah AA, and Ekhzaimy AA. (2018). Differences in the Plasma Proteome of Patients with Hypothyroidism before and after Thyroid Hormone Replacement: A Proteomic Analysis. Int. J. Mol. Sci., 19 (88): 1-17. doi: 10.3390/ijms19010088 [04] Pucci E, Chiovato L and Pinchera A. (2000). Thyroid and lipid metabolism. Inter J Obesity, 24 (2): 109-112. [05] Ganie MA, and Zargar AH. (2007). Scenario of endocrinology in South Asia. Indian J Endocrinol Metab, 11: 1-2. [06] Heuck CC, Kalner A, Kanagasabapathy AS, Riesen W. (2000). Diagnosis and monitoring of the disease of the thyroid. World Health Organization. Pp. 8-9. [07] Ridgway EC. (1996). Modern concepts of primary thyroid gland failure. Clin Chem, 42 (1): 179-182. [08] Zhang G, and Berardi LV. (1998). An investigation of neural networks in thyroid function diagnosis, Health Care Manag Sci, 1 (1): 29-37. [09] Mushtaq S,. Ishaq S, Rashid T, Rasool S, Bhat AA, and Majid S. (2015). DYSLIPIDEMIA IN THYROID DISORDERS. Indo Amer J Pharm Res, 5 (11): 3439-3443. [10] Seely EW, and Williams, GH. (2001). The heart in Endocrine Disorder In: Eugene Braunwald, Douglas P. Zipes. Heart Disease 6^th edition. W. B. Saunders Company, Philadelphia. Pp. 2151-2171. [11] Rizos CV, Elisaf MS, and Liberopoulos EN. (2011). Effects of Thyroid Dysfunction on Lipid Profile. Open Cardiovasc Med J, 5: 76-84. [12] Davis LM, Rho JM, and Sullivan PG. (2008). UCP-mediated free fatty acid uncoupling of isolated cortical mitochondria from fasted animals: correlations to dietary modulations. Epilepsia, 1 (8): 117-119. [13] Galesanu C, Lisnic N, Teslaru R, Apostu L, and Zbranca E. (2004). Lipid profile in a group of hypothyroid patients Vs treated hypothyroid patients. Rev Med Chir Soc Med Nat Iasi, 108 (3): 554-560. [14] Chin KY, Ima-Nirwana S, Mohamed IN, Aminuddin A, Johari MH, and Ngah WZW. (2014). The relationships between thyroid hormones and thyroid-stimulating hormone with lipid profile in euthyroid men Inter J Med Sci, 11 (4): 349-355. [15] Benseñor IM, Goulart AC, Lotufo PA, Menezes PR, and Scazufca M. (2011). Prevalence of thyroid disorders among older people: results from the São Paulo Ageing and Health Study. Cad Saude Publica, 27 (1): 155-161. [16] Valeix P, Dos Santos C, Castetbon K, Bertrais S, Cousty C, and Hercberg S. (2004). Thyroid hormone levels and thyroid dysfunction of French adults participating in the SU.VI.MAX study. Annal Endocrinol, 65 (6): 477-486. [17] Simon H. (2006). Hypothyroidism. University of Maryland Medical Center. Retrieved 2008-02-28. [18] Inada M, Kasagi K, Kurata S, Kazama Y, Takayama H., Torizuka K, Fukase M, and Soma T. (1975). Estimation of thyroxine and triiodothyronine distribution and of the conversion rate of thyroxine to triiodothyronine in man. J Clin Invest, 55: 1337 – 1348. [19] Canaris GJ, Manowitz NR, Mayor G, and Ridgway EC. (2000). The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526-534 [20] Hollowell JG, Staehling NW, Flanders WD, et al. (2002). Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 87: 489-499. [21] Danes MD, Ladenson PW, Meinert CL, and Powe NR. (2000). Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of literature. Clin Endocrinol Meta, 85: 2993-3001. [22] Luboshitzky R, Aviv A, Herer P, and Lavie L. (2002). Risk factors for cardiovascular disease in women with sub-clinical hypothyroidism. Thyroid, 12: 421-425. [23] Vanderpump MP, and Tun bridge WM (1995). French of thyroid disorder in the community: a twenty–year follow–up of the Whickham Survey. Clin Endocrinol (Oxf), 43: 55-68. [24] Jung CH, Sung KC, Shin HS, et al. (2003). Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hs CRP, and waist-hip ratio in Korea. Korean J Inter Med, 18: 146-153. [25] Tanis BC, Westendorp GJ, and Smelt HM. (1996). Effect of thyroid substitution on hypercholesterolaemia in patients with sub-clinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf), 44: 643-649. [26] Walsh JP, Bremner AP, Bulsara MK, et al. (2005). Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol (Oxf), 63: 670-675. [27] El-Habiby MI, Naser L, Morar M, Almasry A, Hasan M, Mohieldein AH. (2017). Association of subclinical hypothyroidism and lipid profile in dyslipidemic patients from Gaza City, Palestine. Sudan Med Monit, 12: 13-17. [28] Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, and Tsatsoulis A. (2005). Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor acetyl hydrolase in patients with sub-clinical hypothyroidism: a potential antiatherogenic effect. Thyroid, 15: 455-460. [29] Toruner F, Altinova AE, Karakoc A, et al. (2008). Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Adv Ther, 25: 430-437. [30] Erdem TY, Ercan M, Ugurlu S, Balci H, Acbay O, and Gundogdu S. (2008). Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidism. Clin Hemorheol Micro, 38: 219-225. [31] Michalopoulou G, Alevizaki M, Piperingos G, et al. (1998). High serum cholesterol levels in persons with high-normal TSH levels: should one extend the definition of sub-clinical hypothyroidism? Eur J Endocrinol, 138: 141-145. [32] Tumbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F et al. (1977). Lipid profiles and cardiovascular disease in the Wickham areas with particular reference to thyroid failure. Clin Endocrinol, 7: 495-508. [33] Jiskra J, Limanova Z, and Antosova M. (2007). Thyroid diseases, dyslipidemia, and cardiovascular risk. Vnitr Lek, 53 (4): 382-385. [34] Liberopoulos EN, and Elisaf MS. (2002). Dyslipidemia in patients with thyroid disorders. Hormones, 1 (4): 218-223. [35] Diekman MJ, Anghelescu N, Endert E, Bakker O, and Wiersinga WM. (2000). Changes in plasma low-density lipoprotein (LDL) - and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thy¬roxine, not to polymorphisms in LDL receptor or choles-terol ester transfer protein genes. J Clin Endocrinol Metab, 85: 1857-1862. [36] Surks MI, Ortiz E, Daniels GH, et al. (2004). Sub-clinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 291 (2): 228-238. [37] Ozyılmaz L, and Yıldırım T. [2002]. Diagnosis of thyroid disease using artificial neural network methods, in: Proceedings of ICONIP’02 9^th international conference on neural information processing, Singapore: Orchid Country Club. pp. 2033–2036. [38] Kung AW, Pang RW, Lauder I, Lam KS, and Janus ED. (1995). Changes in serum lipoprotein (a) and lipids during treatment of hyperthyroidism. Clin Chem, 41: 226-231. [39] Aviram M, Luboshitzky R, and Brook JG. (1982). Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. Clin Biochem, 15: 62-66. [40] Lee WY, Suh JY, Rhee EJ, Park JS, Sung KC, and Kim SW. (2004). Plasma CRP, apolipoprotein A-1, apolipo-protein B and Lp(a) levels according to thyroid function status. Arch Med Res, 35: 540-545. [41] Shrestha N. (2011). Thyroid Dysfunction and its Effect in Serum Lipids. National College for Advanced Learning, Kathmandu, Nepal. J Nepal Health Res Council, 9 (18): 33-37. [42] Zhu X, and Cheng SY. (2010). New insights into regulation of lipid metabolism by thyroid hormone. Current Opinion Endocrinol Diab Obesity, 17 (5): 408-413. [43] Bakker O, Hudig F, Meijssen S, and Wiersinga WM. (1998). Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun, 249: 517-521. [44] Shin DJ, and Osborne TF. (2003). Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element- Binding Protein-2 (SREBP-2). J Biol Chem, 278: 34114-34118. [45] Faure P, Oziol L, Artur Y, and Chomard P. (2004). Thyroid hormone (T3) and its acetic derivative (TA3) protect low-density lipoproteins from oxidation by different mechanisms. Biochimie, 86: 411-418. [46] Lagrost L. (1994). Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta, 1215: 209-36. [47] Kuusi T, Saarinen P, and Nikkila EA. (1980). Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein₂ in man. Atheroscl, 36 (4): 589-593. [48] Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, and Nong Z. (2004). Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol, 24: 1750-1754. [49] Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, and Rodriguez JC. (2005). Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem, 280: 27533-27543. [50] Rensen PC, van Dijk KW, and Havekes LM. (2005). Apolipoprotein AV: low concentration, high impact. Arterioscler Thromb Vasc Biol, 25: 2445-2447. [51] Maduka Ignatius C., Osunbor Joan O., Osunbor Augustine O, and Egwu Mary C. (2018). Evaluation of thyroid function and lipid profile of hypertensive subjects. Merit Res J Med Medical Sci, 6 (4): 160-164. [52] Pearce EN, Wilson PW, Yang Q, Vasan RS, and Braverman LE. (2008). Thyroid function and lipid sub particle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab, 93: 888-94. [53] Abrams J, and Grundy S. (1981). Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J Lipid Res, 22: 323–338. [54] Addgepa D, Macaron C, Mallik T, and Schnuda ND. (1979). Plasma high density lipoprotien cholesterol in thyroid disease. J Clin Endocrinol Metab, 49: 726-729. [55] Al-Tonsi AA, Abdel-Gayoum AA, and Saad M. (2004). The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disorders. Exp Mol Pathol, 76: 182-187. [56] Desai JP, Vachhani UN, Modi G, and Chauhan K. (2015). A study of correlation of serum lipid profile in patients with hypothyroidism. Inter J Med Sci Publ Health, 4 (8): 1108-1112. [57] Duntas LH. (2002). Thyroid disease and lipids. Thyroid, 12 (4): 287-293. [58] Kung AW, Pang RW, Lauder I, Lam KS, and Janus ED. (1995). Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin Chem, 41: 226-231. [59] Kvetny J, Heldgaard PE, Bladbjerg EM, and Gram J.(2004). Sub-clinical hypothyroidism is assocciated with low grade inflammation, increased triglyceride levels edicts cardiovascular disease in male below 50 years. Clin Endocrinol, 61: 232-238.